Kairos Pharma KAPA
NYSE KAPA
$0.56 -0.02 (-3.12%)
As of: Oct 22, 2026 · 11:37 AM EDT

Kairos Pharma (KAPA) Income from Continuing Operations (2023 - 2025)

Updated

Kairos Pharma's Income from Continuing Operations came in at -$5.45 million for FY2025, compared with -$2.38 million in FY2024.

Analysis

Kairos Pharma (KAPA) Income from Continuing Operations (2023 - 2025) Analysis & Trends

  • Per Business Quant, earlier years put Income from Continuing Operations at -$2.38 million in FY2024 and -$1.76 million in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Eli Lilly 1,170.57 Bn 1,139.16 Bn 19.71 Bn 7.10 Bn
2 Johnson & Johnson 641.68 Bn 560.21 Bn 17.26 Bn 5.53 Bn
3 AbbVie 502.16 Bn 475.27 Bn 12.70 Bn 3.62 Bn
4 Merck 375.54 Bn 329.92 Bn 12.21 Bn -1.34 Bn
5 Novartis Ag 302.70 Bn 266.69 Bn 11.24 Bn 3.26 Bn
6 Astrazeneca 268.54 Bn 242.22 Bn 12.86 Bn 2.51 Bn
7 Amgen 242.61 Bn 198.01 Bn 7.24 Bn 2.38 Bn
8 Gilead Sciences 193.36 Bn 167.56 Bn 6.22 Bn -10.50 Bn
9 Pfizer 172.54 Bn 119.18 Bn 10.94 Bn -246.00 Mn
10 Kairos Pharma 10.29 Mn -2.12 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -1.42 Mn
Mar 31, 2025 -1.26 Mn
Dec 31, 2024 -1.45 Mn
Sep 30, 2024 -395,000.00
Jun 30, 2024 -234,000.00
Mar 31, 2024 -303,000.00
Dec 31, 2023 -1.09 Mn
Sep 30, 2023 -302,000.00
API Access

Kairos Pharma Income from Continuing Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=KAPA&period=max&api_key=YOUR_API_KEY